The short version of Freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-25. Anything still debated is marked as such rather than presented as settled.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
The only primordial isotope of bismuth, bismuth-209, had long been regarded as the heaviest stable nuclide, but was suspected on theoretical grounds to be unstable to alpha decay. This was finally demonstrated in 2003, when researchers at the Institut d'astrophysique spatiale in Orsay, France, detected this decay; the best value of the half-life is now 2.01×1019 years (3 Bq/t), over 109 times longer than the estimated age of the universe. Due to its hugely long half-life, for all known medical and industrial applications, bismuth can be treated as stable. The radioactivity is of academic interest because bismuth is one of a few elements whose radioactivity was suspected and theoretically predicted before being detected in the laboratory. Bismuth has the longest known α-decay half-life, though tellurium-128 has the longest known by any mode: double beta decay at about 2.25×1024 years. Six isotopes of bismuth with short half-lives (210–215 inclusive, but not 210m) occur in the natural radioactive decay chains of actinium, radium, thorium, and neptunium, and more have been synthesized. (Though all primordial 237Np has long since decayed, it is continually regenerated by (n,2n) knockout reactions on natural 238U.) For medical use, bismuth-213 can be produced, as the parent isotope actinium-225, by bombarding radium with bremsstrahlung photons from a linear particle accelerator.
== Research == Trimebutine is investigated for the treatment of functional dyspepsia-IBS overlap syndrome, post-operative nausea and vomiting. A clinical trial evaluating trimebutine as an adjunctive treatment to rabeprazole-resistant reflux oesophageitis was withdrawn due to lack of funds.
=== Ecuador's expulsion of Cuban ambassador === On 4 March 2026, Ecuador expelled Cuban Ambassador Basilio Gutierrez and his staff, declaring them persona non grata. No reason was provided for the expulsion.
Wax, used in the packaging of frozen foods, among others, paraffin wax, derived from petroleum oil. Sulfur and its derivative sulfuric acid. Hydrogen sulfide is a product of sulfur removal from petroleum fraction. It is oxidized to elemental sulfur and then to sulfuric acid. Bulk tar and asphalt. Petroleum coke, used in speciality carbon products or as solid fuel.
Sources: en.wikipedia.org
Spironolactone is widely used as an antiandrogen in feminizing hormone therapy for transfeminine people and is recommended by transgender medicine clinical guidelines for such purposes. It is the most commonly used antiandrogen in transfeminine people in the United States, whereas cyproterone acetate (CPA), which is not available in the United States, is widely used in Europe and throughout the rest of the world. Spironolactone is inferior to CPA, other progestogens, GnRH modulators, and high-dose parenteral estradiol monotherapy in terms of achieving adequate testosterone suppression in transfeminine people. However, spironolactone acts as a direct though weak androgen receptor antagonist rather than by suppressing testosterone levels, and hence its antiandrogenic effects and potential therapeutic benefits in this context are not necessarily reflected in testosterone levels. In any case, while widely used, there remain very limited comparative clinical data on spironolactone versus other antiandrogenic approaches in terms of physical feminization outcomes in transfeminine people.
The exiled mayor of occupied Melitopol, Ivan Fedorov reported an explosion in the city center which led to outages in water, telecommunications and electricity in the eastern and northern districts of the city as well as surrounding villages; pro-Russian authorities confirmed the explosion and the power outage. Novaya Gazeta reported that an improvised explosive device was planted in a rubbish bin near an apartment block where the Russian-installed acting "deputy minister" of construction and public utilities lived, which exploded and injured him when he exited the building.
Aquaphor was developed in 1925 in the United States laboratories of Beiersdorf Inc. It was trademarked that year by Herman A. Metz, the company's president. In 1929, Beiersdorf sold the Aquaphor trademarks to Duke Laboratories to facilitate manufacturing in the country. In 1936, Aquaphor's first product offering was sold to doctors, pharmacists and hospitals in 5 lb. containers. Production was discontinued during World War II but resumed by Duke Laboratories in 1960. At that time, 1 lb cans and 2 oz tubes were sold to medical professionals. Beiersdorf repurchased the trademarks from Duke Laboratories in 1973. In 1982, the product was sold directly to consumers for the first time. The formulation was expanded in 1991 with the launch of "Advanced Therapy Healing Ointment", an addition to the original ointment. Beiersdorf further expanded the brand in the early 2000s, introducing baby products in 2003 and a lip repair line in 2011. In 2012, the brand launched globally in 25 other countries. In 2013, Aquaphor achieved the Good Housekeeping Seal.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.